Ana Grgičević
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Grgičević has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Danijela Barić
Group for Computational Life Sciences, Division of Physical Chemistry, Ruđer Bošković Institute, Bijenička cesta 54, HR-10 000 Zagreb, Croatia
1 shared publication - Irena Škorić
Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Trg Marka Marulića 19, HR-10 000 Zagreb, Croatia
1 shared publication - Nikolina Maček Hrvat
Institute for Medical Research and Occupational Health, Zagreb, Croatia
1 shared publication - Ramiza Ahmetović
Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulicev trg 19, 10000 Zagreb, Croatia
1 shared publication - Tena Čadež
Division of Toxicology, Institute for Medical Research and Occupational Health, Ksaverska cesta 2, HR-10000, Zagreb, Croatia
1 shared publication - Zrinka Kovarik
Institute for Medical Research and Occupational Health, Zagreb, Croatia; Faculty of Science, University of Zagreb, Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
Benzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors
A library of amine, oxime, ether, epoxy and acyl derivatives of the benzobicyclo[3.2.1]octene were synthesized and evaluated as inhibitors of both human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The majority of the tested compounds exhibited higher selectivity for BChE. Structural adjustment for AChE seems to have been achieved by acylation, and the furan ring opening of furo-benzobicyclo[3.2.1]octadiene results for compound 51 with the highest AChE affinity (IC50 = 8.3 µM). Interestingly, its analogue, an oxime ether with a benzobicyclo[3.2.1]-skeleton, compound 32 was one of the most potent BChE inhibitors in this study (IC50 = 31 µM), but not as potent as endo-43, an ether derivative of the benzobicyclo[3.2.1]octene with an additional phenyl substituent (IC50 = 17 µM). Therefore, we identified several cholinesterase inhibitors with a potential for further development as potential drugs for the treatment of neurodegenerative diseases.
Open AccessBenzobicyclo[3.2.1]octene Derivatives as a New Class of Cholinesterase Inhibitors
A library of amine, oxime, ether, epoxy and acyl derivatives of the benzobicyclo[3.2.1]octene were synthesized and evaluated as inhibitors of both human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The majority of the tested compounds exhibited higher selectivity for BChE. Structural adjustment for AChE seems to have been achieved by acylation, and the furan ring opening of furo-benzobicyclo[3.2.1]octadiene results for compound 51 with the highest AChE affinity (IC50 = 8.3 µM). Interestingly, its analogue, an oxime ether with a benzobicyclo[3.2.1]-skeleton, compound 32 was one of the most potent BChE inhibitors in this study (IC50 = 31 µM), but not as potent as endo-43, an ether derivative of the benzobicyclo[3.2.1]octene with an additional phenyl substituent (IC50 = 17 µM). Therefore, we identified several cholinesterase inhibitors with a potential for further development as potential drugs for the treatment of neurodegenerative diseases.